Clinical Trial Update: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating the efficacy and safety of AGB101 for Parkinson disease-related psychosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AGB101

Snippet

Sponsor: Johns Hopkins University | Conditions: Parkinson Disease Psychosis | Phase 2 | Status: RECRUITING